Stealth designs to overcome allorejection in engineered cell therapy
Trends in Immunology · 2026-08 · 47 (8) · 716-731
DOI: 10.1016/j.it.2026.02.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Immunology, 2026-08. Verfasst von Yan-Ruide Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioen…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Cell- and Tissue-Based Therapy, Cell Engineering, Graft Rejection. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of California Los Angeles, Parker Institute for Cancer Immunotherapy.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 9009…
Förderung
- University of California Los Angeles
- Parker Institute for Cancer Immunotherapy
Zitieren
APA
Li, Y. R., Chen, Y., & Yang, L. (2026). Stealth designs to overcome allorejection in engineered cell therapy. Trends in Immunology, 47(8), 716-731. https://doi.org/10.1016/j.it.2026.02.008
Vancouver
Li YR, Chen Y, Yang L. Stealth designs to overcome allorejection in engineered cell therapy. Trends in Immunology. 2026;47(8):716-731. doi:10.1016/j.it.2026.02.008
BibTeX
@article{Li2026,
author = {Li, Yan-Ruide and Chen, Yuning and Yang, Lili},
title = {Stealth designs to overcome allorejection in engineered cell therapy},
journal = {Trends in Immunology},
year = {2026},
volume = {47},
number = {8},
pages = {716--731},
doi = {10.1016/j.it.2026.02.008}
}
EUVIMED